Institutional Investors Bolster Positions in Johnson & Johnson Amid Insider Sales

Major funds boost J&J stakes as insiders sell $7.36M in shares. Stock yields 2.1%, trades above target after strong Q4 results with 28.5% net margin.

Recent regulatory filings reveal a notable divergence in trading activity surrounding healthcare giant Johnson & Johnson. While major institutional asset managers have been significantly increasing their stakes, corporate insiders have opted to sell substantial holdings.

Fund Managers Expand Exposure

Several investment firms reported enlarging their positions in the company during the third quarter. Mitsubishi UFJ Asset Management boosted its holdings by 4.3%, bringing its total to 5,030,835 shares, representing an investment worth approximately $932.8 million. An even more pronounced increase was recorded by Empirical Asset Management LLC, which expanded its position by 80.7% to 9,582 shares, valued at around $1.78 million.

Smaller funds also demonstrated strong buying interest. Compass Financial increased its stake by a substantial 707.1% to 226 shares, while Semmax Financial grew its holdings by 55.0% to 203 shares. Collectively, institutional investors now control 69.55% of the company's outstanding shares. This accumulation stands in contrast to the actions of company insiders, who divested 30,142 shares worth a combined $7.36 million over a 90-day period.

Financial Performance and Corporate Updates

The stock began trading ex-dividend on February 24, 2026. Shareholders of record are set to receive a quarterly distribution of $1.30 per share on March 10, 2026. This equates to an annualized dividend of $5.20, yielding approximately 2.1% based on the current share price. The payout ratio is calculated at 46% of earnings and 64% of free cash flow.

Fourth-quarter results, released on January 31, 2026, showed earnings per share of $2.46 on revenue of $24.28 billion. The company achieved a net margin of 28.46%. On the regulatory front, Johnson & Johnson has submitted an expanded application for its drug Nipocalimab to the U.S. Food and Drug Administration. Separately, its Janssen subsidiary is involved in litigation initiated by Bayer.

Johnson & Johnson shares recently traded at $245.32, a level that exceeds the average analyst price target of $232.70. The broad-based institutional accumulation signals continued confidence in the firm's earnings potential, even as some executives capitalized on recent price strength to liquidate portions of their holdings.